Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285439 · ClinicalTrials.gov registry record · Phase 1
Study of MEK162 for Children With Low-Grade Gliomas
A Phase 1 study, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT02285439 is a Phase 1 study that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 105 participants.
The verdict
NCT02285439, a Phase 1 study, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are: What is the correct dose of MEK162 in children? What are the side effects of MEK162 in children? Is MEK162 effective in children with low-grade glioma? Participants on the study receive MEK162 by mouth twice daily for up to 2 years.
Interventions
- DRUG MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285439
The ClinicalTrials.gov registry entry for NCT02285439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEK162 is the first listed.
NCT02285439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285439 about?
NCT02285439 is a clinical study titled "Study of MEK162 for Children With Low-Grade Gliomas". The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are: What is the correct dose of MEK162 in child...
What is the current status of trial NCT02285439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2016-05-04. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT02285439?
The interventions under investigation include: MEK162 (DRUG).
Who is sponsoring clinical trial NCT02285439?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.